|
Q2 FY2025
As of Jun 30, 2026
|
Q1 FY2025
As of Mar 31, 2026
|
Q4 FY2024
As of Dec 31, 2025
|
Q3 FY2024
As of Sep 30, 2025
|
Q2 FY2024
As of Jun 30, 2025
|
Q1 FY2024
As of Mar 31, 2025
|
Q4 FY2023
As of Dec 31, 2024
|
Q3 FY2023
As of Sep 30, 2024
|
Q2 FY2023
As of Jun 30, 2024
|
Q1 FY2023
As of Mar 31, 2024
|
Q4 FY2022
As of Dec 31, 2023
|
Q3 FY2022
As of Sep 30, 2023
|
Q2 FY2022
As of Jun 30, 2023
|
Q1 FY2022
As of Mar 31, 2023
|
Q4 FY2021
As of Dec 31, 2022
|
Q3 FY2021
As of Sep 30, 2022
|
Q2 FY2021
As of Jun 30, 2022
|
Q4 FY2020
As of Dec 31, 2021
|
Q1 FY2021
As of Mar 31, 2022
|
Q3 FY2020
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS: | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Health plan receivable, net of allowance for credit losses of $281 | ||||||||||||||||||||
| Clinic fees, insurance and other receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| TOTAL CURRENT ASSETS | ||||||||||||||||||||
| Property and Equipment | ||||||||||||||||||||
| Less: Accumulated Depreciation | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Right of Use Asset | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Accrued payroll | ||||||||||||||||||||
| Health plan settlements payable | ||||||||||||||||||||
| Claims payable | ||||||||||||||||||||
| Premium deficiency reserve | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Short-term debt | ||||||||||||||||||||
| TOTAL CURRENT LIABILITIES | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Operating lease liability, net | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Contingent consideration | ||||||||||||||||||||
| Long-term debt, net | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| MEZZANINE EQUITY: | ||||||||||||||||||||
| Redeemable non-controlling interest | ||||||||||||||||||||
| Common stock, shares issued (in shares) | ||||||||||||||||||||
| Class A Common Stock | ||||||||||||||||||||
| Class V Common Stock | ||||||||||||||||||||
| Common stock, shares outstanding (in shares) | ||||||||||||||||||||
| Class A Common Stock | ||||||||||||||||||||
| Class V Common Stock | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY (DEFICIT): | ||||||||||||||||||||
| Preferred stock | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Series C Preferred Stock | ||||||||||||||||||||
| Series D Preferred Stock | ||||||||||||||||||||
| Common stock | ||||||||||||||||||||
| Class A Common Stock | ||||||||||||||||||||
| Class V Common Stock | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||||||||||||||
| TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
| TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
Loading...